STAT3 and cancer: Thus, SBT-100 is a “First-in-Class” anticancer agent for targeting STAT3 and KRAS simultaneously in cancers and provides proof of concept for this novel approach to treating cancer and other diseases by focusing on aberrant intracellular targets.